内科理论与实践

内科理论与实践 >

2022 , Vol. 17 >Issue 05: 418 - 422

DOI: https://doi.org/10.16138/j.1673-6087.2022.05.015

综述

呼出气一氧化氮在下气道慢性炎症疾病中的评估价值

展开
  • 山西医科大学第二医院呼吸与危重症医学科,山西 太原 030001

收稿日期: 2021-10-14

  网络出版日期: 2022-11-04

收起

Value of exhaled nitric oxide in evaluating lower airway chronic inflammatory disease

Expand

Received date: 2021-10-14

  Online published: 2022-11-04

Fold

本文引用格式

闫晓红, 薄建萍 . 呼出气一氧化氮在下气道慢性炎症疾病中的评估价值[J]. 内科理论与实践, 2022 , 17(05) : 418 -422 . DOI: 10.16138/j.1673-6087.2022.05.015

参考文献

[1] Mummadi SR, Hahn PY. Update on exhaled nitric oxide in clinical practice[J]. Chest, 2016, 149(5): 1340-1344.
[2] Harnan SE, Tappenden P, Essat M, et al. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath[J]. Health Technol Assess, 2015, 19(82): 1-330.
[3] Anavi S, Tirosh O. iNOS as a metabolic enzyme under stress conditions[J]. Free Radic Biol Med, 2020, 146: 16-35.
[4] Stewart L, Katial RK. Exhaled nitric oxide[J]. Immunol Allergy Clin North Am, 2012, 32(3): 347-362.
[5] Pappalardo MG, Parisi GF, Tardino L, et al. Measurement of nitric oxide and assessment of airway diseases in children: an update[J]. Minerva Pediatr, 2019, 71(6): 524-532.
[6] Cyr AR, Huckaby LV, Shiva SS, et al. Nitric oxide and endothelial dysfunction[J]. Crit Care Clin, 2020, 36(2): 307-321.
[7] Högman M, Thornadtsson A, Bröms K, et al. Different relationships between FENO and COPD characteristics in smokers and ex-smokers[J]. COPD, 2019, 16(3-4): 227-233.
[8] Horváth I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease[J]. Eur Respir J, 2017, 49(4): 1600965.
[9] Hoyte FCL, Gross LM, Katial RK. Exhaled nitric oxide: an update[J]. Immunol Allergy Clin North Am, 2018, 38(4): 573-585.
[10] Arnold RJ, Massanari M, Lee TA, et al. A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (FeNO) in asthma management[J]. Manag Care, 2018, 27(7): 34-41.
[11] GBD 015 Chronic Respiratory Disease Collaborators. 2Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017, 5(9): 691-706.
[12] Rupani H, Chauhan AJ. Measurement of FeNO in asthma: what the hospital doctor needs to know[J]. Br J Hosp Med (Lond), 2019, 80(2): 99-104.
[13] Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology[J]. J Allergy Clin Immunol, 2016, 137(5): 1347-1358.
[14] Pavlidis S, Takahashi K, Ng Kee Kwong F, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin[J]. Eur Respir J, 2019, 53(1): 1800938.
[15] Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice[J]. J Allergy Clin Immunol, 2016, 138(5): 1296-1298.
[16] Chen LC, Zeng GS, Wu LL, et al. Diagnostic value of FeNO and MMEF for predicting cough variant asthma in chronic cough patients with or without allergic rhinitis[J]. J Asthma, 2021, 58(3): 326-333.
[17] 中国医药教育协会慢性气道疾病专业委员会, 中国哮喘联盟. 呼出气一氧化氮检测及其在气道疾病诊治中应用的中国专家共识[J]. 中华医学杂志, 2021, 101(38): 3092-3114.
[18] Halpin DMG, Celli BR, Criner GJ, et al. The GOLD summit on chronic obstructive pulmonary disease in low- and middle-income countries[J]. Int J Tuberc Lung Dis, 2019, 23(11): 1131-1141.
[19] Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, et al. Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review protocol[J]. BMJ Open, 2017, 7(12): e018954.
[20] Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease[J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36.
[21] Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2016, 138(1): 16-27.
[22] Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, et al. Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap(ACO)[J]. COPD, 2018, 15(4): 377-391.
[23] Yamaji Y, Oishi K, Hamada K, et al. Detection of type2 biomarkers for response in COPD[J]. J Breath Res, 2020, 14(2): 026007.
[24] Tang B, Huang D, Wang J, et al. Relationship of blood eosinophils with fractional exhaled nitric oxide and pulmonary function parameters in chronic obstructive pulmonary disease (COPD) exacerbation[J]. Med Sci Monit, 2020, 26: e921182.
[25] Antus B, Paska C, Barta I. Predictive value of exhaled nitric oxide and blood eosinophil count in the assessment of airway eosinophilia in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2025-2035.
[26] Gong S, Pu Y, Xie L, et al. Fraction of exhaled nitric oxide is elevated in patients with stable chronic obstructive pulmonary disease[J]. Am J Med Sci, 2020, 360(2): 166-175.
[27] Matsunaga K, Kuwahira I, Hanaoka M, et al. An official JRS statement: the principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice[J]. Respir Investig, 2021, 59(1): 34-52.
[28] Rhee CK, Chau NQ, Yunus F, et al. Management of COPD in Asia: a position statement of the Asian Pacific Society of Respirology[J]. Respirology, 2019, 24(10): 1018-1025.
[29] Imam JS, Duarte AG. Non-CF bronchiectasis: orphan disease no longer[J]. Respir Med, 2020, 166: 105940.
[30] Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity[J]. Lancet, 2018, 392(10150): 880-890.
[31] Chai YH, Xu JF. How does Pseudomonas aeruginosa affect the progression of bronchiectasis?[J]. Clin Microbiol Infect, 2020, 26(3): 313-318.
[32] Luo RG, Miao XY, Luo LL, et al. Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients[J]. Clin Microbiol Infect, 2019, 25(5): 601-606.
[33] Tsikrika S, Dimakou K, Papaioannou AI, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis[J]. Cytokine, 2017, 99: 281-286.
[34] Lucas JS, Davis SD, Omran H, et al. Primary ciliary dyskinesia in the genomics age[J]. Lancet Respir Med, 2020, 8(2): 202-216.
[35] Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children[J]. Eur Respir J, 2020, 55(1): 1901136.
[36] Diver S, Russell RJ, Brightling CE. Cough and eosinophilia[J]. J Allergy Clin Immunol Pract, 2019, 7(6): 1740-1747.
[37] Côté A, Russell RJ, Boulet LP, et al. Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report[J]. Chest, 2020, 158(1): 68-96.
[38] Tang W, Zhou J, Miao L, et al. Clinical features in patients of cough variant asthma with normal and high level of exhaled fractional nitric oxide[J]. Clin Respir J, 2018, 12(2): 595-600.
[39] Lamon T, Didier A, Brouquières D, et al. Exhaled nitric oxide in chronic cough: a good tool in a multi-step approach[J]. Respir Med Res, 2019, 76: 4-9.
[40] Maniscalco M, Fuschillo S, Gaudiosi C, et al. Exhaled and nasal nitric oxide measurement in the evaluation of chronic cough[J]. Nitric Oxide, 2019, 83: 19-23.
[41] Swaminathan AC, Carney JM, Tailor TD, et al. Overview and challenges of bronchiolar disorders[J]. Ann Am Thorac Soc, 2020, 17(3): 253-263.
[42] He F, Gong HY, Jiang GL, et al. Diffuse panbronchiolitis: a case report from a Chinese consanguineous marriage family and literature review[J]. Chron Respir Dis, 2020, 17: 1479973120961847.
[43] Faure E, Kwong K, Nguyen D. Pseudomonas aeruginosa in chronic lung infections: how to adapt within the host?[J]. Front Immunol, 2018, 9: 2416.
[44] Xu B, Mao Y, Wan X, et al. Prognostic value of concomitant bronchiectasis in newly diagnosed diffuse panbronchiolitis patients on a maintenance therapy with macrolides[J]. Can Respir J, 2019, 2019: 4913814.
[45] Takeyama K, Shimizu Y, Ishii M, et al. Coexistence of diffuse panbronchiolitis and asthma: reciprocity of neutrophilic and eosinophilic inflammation[J]. Respirol Case Rep, 2017, 5(3): e00232.
Options
文章导航

/

〈 〉